Immunodeviation
K |
|||
| (10 dazwischenliegende Versionen von einem Benutzer werden nicht angezeigt) | |||
| Zeile 1: | Zeile 1: | ||
| + | {{up|PHA Biologicals}} | ||
| + | |||
'''Macrophages''' | '''Macrophages''' | ||
{{tp|p=32335290|t=2020. A strategy targeting monocyte-macrophage differentiation to avoid pulmonary complications in SARS-Cov2 infection |pdf=|usr=}} | {{tp|p=32335290|t=2020. A strategy targeting monocyte-macrophage differentiation to avoid pulmonary complications in SARS-Cov2 infection |pdf=|usr=}} | ||
| Zeile 6: | Zeile 8: | ||
'''Devvac BCG''' | '''Devvac BCG''' | ||
| + | {{ttp|p=32420947|t=2020. Stop playing with data: there is no sound evidence that Bacille Calmette-Guerin may avoid SARS-CoV-2 infection (for now).|pdf=|usr=007}} | ||
{{tp|p=32379923|t=2020. Is BCG vaccination causally related to reduced COVID-19 mortality?|pdf=|usr=}} | {{tp|p=32379923|t=2020. Is BCG vaccination causally related to reduced COVID-19 mortality?|pdf=|usr=}} | ||
{{tp|p=32327396|t=ä. COVID-19 and Bacillus Calmette-Guerin: What is the Link?|pdf=|usr=}} | {{tp|p=32327396|t=ä. COVID-19 and Bacillus Calmette-Guerin: What is the Link?|pdf=|usr=}} | ||
| Zeile 14: | Zeile 17: | ||
{{tp|p=32339299|t=2020. Is global BCG vaccination-induced trained immunity relevant to the progression of SARS-CoV-2 pandemic?|pdf=|usr=}} | {{tp|p=32339299|t=2020. Is global BCG vaccination-induced trained immunity relevant to the progression of SARS-CoV-2 pandemic?|pdf=|usr=}} | ||
{{tp|p=32330314|t=2020. Is BCG vaccination affecting the spread and severity of COVID-19?|pdf=|usr=}} | {{tp|p=32330314|t=2020. Is BCG vaccination affecting the spread and severity of COVID-19?|pdf=|usr=}} | ||
| − | + | {{tp|p=32295694|t=2020. COVID-19 vaccination clinical trials should consider multiple doses of BCG |pdf=|usr=}} | |
{{tp|p=32408071|t=2020. Relation between BCG coverage rate and COVID-19 infection worldwide |pdf=|usr=}} | {{tp|p=32408071|t=2020. Relation between BCG coverage rate and COVID-19 infection worldwide |pdf=|usr=}} | ||
{{tp|p=C7136957|t=ä. Is Global BCG Vaccination Coverage Relevant To The Progression Of SARS-CoV-2 Pandemic?|pdf=|usr=}} | {{tp|p=C7136957|t=ä. Is Global BCG Vaccination Coverage Relevant To The Progression Of SARS-CoV-2 Pandemic?|pdf=|usr=}} | ||
| − | + | {{tp|p=32519258|t=2020. BCG Vaccination Policy and Protection Against COVID-19.|pdf=|usr=008}} | |
| − | + | {{tp|p=32406253|t=2020. Bacillus Calmette Guerin (BCG) vaccination use in the fight against COVID-19 - what's old is new again?|pdf=|usr=008}} | |
| + | {{tp|p=32442946|t=2020. BCG versus COVID-19?|pdf=|usr=007}} | ||
'''Devvac Hepatitis A''' | '''Devvac Hepatitis A''' | ||
{{tp|p=32279655|t=2020. Can Hepatitis A Vaccine Provide Protection Against COVID-19?|pdf=|usr=}} | {{tp|p=32279655|t=2020. Can Hepatitis A Vaccine Provide Protection Against COVID-19?|pdf=|usr=}} | ||
| − | + | {{tp|p=32401274|t=2020. SARS-CoV-2 Rates in BCG-Vaccinated and Unvaccinated Young Adults.|pdf=|usr=009}} | |
| + | {{tp|p=32393823|t=2020. BCG-induced trained immunity: can it offer protection against COVID-19?|pdf=|usr=009}} | ||
| + | {{tp|p=32417996|t=2020. BCG versus COVID-19: impact on urology.|pdf=|usr=009}} | ||
| + | {{tp|p=32578215|t=2020. Could Anti-Tubercular Vaccination Protect Against Covid-19 Infection?|pdf=|usr=010}} | ||
| + | {{tp|p=32555367|t=2020. Regional BCG vaccination policy in former East- and West Germany may impact on both severity of SARS-CoV-2 and incidence of childhood leukemia.|pdf=|usr=010}} | ||
| + | {{tp|p=32558034|t=2020. National policies for paediatric universal BCG vaccination were associated with decreased mortality due to COVID-19.|pdf=|usr=010}} | ||
| + | {{tp|p=32574258|t=2020. Could BCG Vaccination Induce Protective Trained Immunity for SARS-CoV-2?|pdf=|usr=011}} | ||
| + | {{tp|p=32590235|t=2020. TB infection and BCG vaccination: are we protected from COVID-19?|pdf=|usr=011}} | ||
'''Devvac Measles''' | '''Devvac Measles''' | ||
{{tp|p=32238614|t=2020. Measles Immunization: Worth Considering Containment Strategy for SARS-CoV-2 Global Outbreak |pdf=|usr=}} | {{tp|p=32238614|t=2020. Measles Immunization: Worth Considering Containment Strategy for SARS-CoV-2 Global Outbreak |pdf=|usr=}} | ||
| + | {{tp|p=32501133|t=2020. Vaccine repurposing approach for preventing COVID 19: can MMR vaccines reduce morbidity and mortality?|pdf=|usr=007}} | ||
'''Devvac Influenza''' | '''Devvac Influenza''' | ||
{{tp|p=32361099|t=2020. The possible beneficial adjuvant effect of influenza vaccine to minimize the severity of COVID-19 |pdf=|usr=}} | {{tp|p=32361099|t=2020. The possible beneficial adjuvant effect of influenza vaccine to minimize the severity of COVID-19 |pdf=|usr=}} | ||
| − | ''' | + | '''Devvac VZV''' |
| − | {{tp|p= | + | {{tp|p=16043204|t=2005. (+)Long-term protection from SARS coronavirus infection conferred by a single immunization with an attenuated VSV-based vaccine |pdf=|usr=}} |
| + | |||
'''Devacc''' | '''Devacc''' | ||
{{ttp|p=32240961|t=2020. Routine childhood immunization may protect against COVID-19 |pdf=|usr=}} | {{ttp|p=32240961|t=2020. Routine childhood immunization may protect against COVID-19 |pdf=|usr=}} | ||
{{tp|p=32387756|t=2020. SARS ? CoV-2: Reasons of epidemiology of severe ill disease cases and therapeutic approach using trivalent vaccine (tetanus, diphtheria and Bordetella pertussis) |pdf=|usr=}} | {{tp|p=32387756|t=2020. SARS ? CoV-2: Reasons of epidemiology of severe ill disease cases and therapeutic approach using trivalent vaccine (tetanus, diphtheria and Bordetella pertussis) |pdf=|usr=}} | ||
| − | + | {{tp|p=32440665|t=2020. Cross-Protection Induced by Encephalitis Vaccines against COVID-19 Might be a Reason for Relatively Lower Mortality Rate in Some Countries.|pdf=|usr=008}} | |
| + | {{tp|p=32527819|t=2020. Can existing live vaccines prevent COVID-19?|pdf=|usr=008}} | ||
| + | {{tp|p=32480250|t=2020. Protective effects of vaccinations and endemic infections on COVID-19: A hypothesis.|pdf=|usr=009}} | ||
| + | {{tp|p=32561657|t=2020. Could an Unrelated Live Attenuated Vaccine Serve as a Preventive Measure To Dampen Septic Inflammation Associated with COVID-19 Infection?|pdf=|usr=010}} | ||
| + | {{tp|p=32582766|t=2020. Does Early Childhood Vaccination Protect Against COVID-19?|pdf=|usr=011}} | ||
'''anybody remembers old lit on mcns: acacia akazien-extrakt''' | '''anybody remembers old lit on mcns: acacia akazien-extrakt''' | ||
| Zeile 44: | Zeile 61: | ||
{{tp|p=32300868|t=ä. Balneotherapy and human immune function in the era of COVID-19 |pdf=|usr=}} | {{tp|p=32300868|t=ä. Balneotherapy and human immune function in the era of COVID-19 |pdf=|usr=}} | ||
| − | ''' | + | '''mycobacteria''' |
{{tp|p=32367857|t=2020. Safety of an immunomodulator Mycobacterium w in COVID-19 |pdf=|usr=}} | {{tp|p=32367857|t=2020. Safety of an immunomodulator Mycobacterium w in COVID-19 |pdf=|usr=}} | ||
| + | {{tp|p=32493028|t=2020. Letter to the Editor: Repurposing of an Antisepsis Drug in COVID-19 Patients.|pdf=https://www.liebertpub.com/doi/10.1089/adt.2020.994|usr=007}} ''Mw ensues strong immune reaction and generates robust cytokines such as interleukin-2, interferon-γ, and T cell responses.'' | ||
| + | |||
| + | '''Helminthiosis''' | ||
| + | {{tp|p=32358579|t=ä. Will helminth co-infection modulate COVID-19 severity in endemic regions?|pdf=|usr=}} | ||
| + | |||
| + | |||
| + | '''immunomodulation immunotherapies''' | ||
| + | |||
| + | {{tp|p=32380023|t=ä. Immunomodulation in COVID-19 |pdf=|usr=}} | ||
| + | {{tp|p=32444269|t=ä. Immunotherapies for COVID-19: lessons learned from sepsis |pdf=|usr=}} | ||
| + | {{tp|p=32383371|t=2020. Perspectives of Immune Therapy in Coronavirus Disease 2019.|pdf=|usr=008}} | ||
| + | {{tp|p=32499129|t=2020. Immunotherapies for COVID-19: Restoring the immunity could be the priority.|pdf=|usr=008}} | ||
| + | {{tp|p=32452670|t=2020. Immunity-Boosting Spices and the Novel Coronavirus.|pdf=|usr=008}} | ||
| + | {{tp|p=32468851|t=2020. Facing the SARS-CoV-2 outbreak in the immunotherapy era.|pdf=|usr=008}} | ||
| + | {{tp|p=32534022|t=2020. COVID-19 and allergen immunotherapy: theoretical benefits invite to adjustments in practice recommendations.|pdf=|usr=008}} | ||
| + | {{tp|p=C7190525|t=2020. Adjunct Immunotherapies for the Management of Severely Ill COVID-19 Patients |pdf=|usr=}} | ||
| + | {{tp|p=32404512|t=2020. Can Unconventional Immunomodulatory Agents Help Alleviate COVID-19 Symptoms and Severity?|pdf=|usr=009}} | ||
| + | {{tp|p=32604407|t=2020. Immune modulation in COVID-19: Strategic considerations for personalized therapeutic intervention.|pdf=|usr=011}} | ||
Aktuelle Version vom 18. Januar 2021, 20:52 Uhr
| PHA Biologicals |
Macrophages
32335290 2020. A strategy targeting monocyte-macrophage differentiation to avoid pulmonary complications in SARS-Cov2 infection
32374474 2020. Natural antiviral compound silvestrol modulates human monocyte-derived macrophages and dendritic cells
Devvac BCG
| 32420947 2020. Stop playing with data: there is no sound evidence that Bacille Calmette-Guerin may avoid SARS-CoV-2 infection (for now). |
32379923 2020. Is BCG vaccination causally related to reduced COVID-19 mortality?
32327396 ä. COVID-19 and Bacillus Calmette-Guerin: What is the Link?
32358227 2020. Demystifying BCG Vaccine and COVID-19 Relationship
32341531 ä. Could BCG be used to protect against COVID-19?
32372835 2020. Trials of BCG vaccine will test for covid-19 protection
32359402 2020. Considering BCG vaccination to reduce the impact of COVID-19
32339299 2020. Is global BCG vaccination-induced trained immunity relevant to the progression of SARS-CoV-2 pandemic?
32330314 2020. Is BCG vaccination affecting the spread and severity of COVID-19?
32295694 2020. COVID-19 vaccination clinical trials should consider multiple doses of BCG
32408071 2020. Relation between BCG coverage rate and COVID-19 infection worldwide
C7136957 ä. Is Global BCG Vaccination Coverage Relevant To The Progression Of SARS-CoV-2 Pandemic?
32519258 2020. BCG Vaccination Policy and Protection Against COVID-19.
32406253 2020. Bacillus Calmette Guerin (BCG) vaccination use in the fight against COVID-19 - what's old is new again?
32442946 2020. BCG versus COVID-19?
Devvac Hepatitis A
32279655 2020. Can Hepatitis A Vaccine Provide Protection Against COVID-19?
32401274 2020. SARS-CoV-2 Rates in BCG-Vaccinated and Unvaccinated Young Adults.
32393823 2020. BCG-induced trained immunity: can it offer protection against COVID-19?
32417996 2020. BCG versus COVID-19: impact on urology.
32578215 2020. Could Anti-Tubercular Vaccination Protect Against Covid-19 Infection?
32555367 2020. Regional BCG vaccination policy in former East- and West Germany may impact on both severity of SARS-CoV-2 and incidence of childhood leukemia.
32558034 2020. National policies for paediatric universal BCG vaccination were associated with decreased mortality due to COVID-19.
32574258 2020. Could BCG Vaccination Induce Protective Trained Immunity for SARS-CoV-2?
32590235 2020. TB infection and BCG vaccination: are we protected from COVID-19?
Devvac Measles
32238614 2020. Measles Immunization: Worth Considering Containment Strategy for SARS-CoV-2 Global Outbreak
32501133 2020. Vaccine repurposing approach for preventing COVID 19: can MMR vaccines reduce morbidity and mortality?
Devvac Influenza
32361099 2020. The possible beneficial adjuvant effect of influenza vaccine to minimize the severity of COVID-19
Devvac VZV
16043204 2005. (+)Long-term protection from SARS coronavirus infection conferred by a single immunization with an attenuated VSV-based vaccine
Devacc
| 32240961 2020. Routine childhood immunization may protect against COVID-19 |
32387756 2020. SARS ? CoV-2: Reasons of epidemiology of severe ill disease cases and therapeutic approach using trivalent vaccine (tetanus, diphtheria and Bordetella pertussis)
32440665 2020. Cross-Protection Induced by Encephalitis Vaccines against COVID-19 Might be a Reason for Relatively Lower Mortality Rate in Some Countries.
32527819 2020. Can existing live vaccines prevent COVID-19?
32480250 2020. Protective effects of vaccinations and endemic infections on COVID-19: A hypothesis.
32561657 2020. Could an Unrelated Live Attenuated Vaccine Serve as a Preventive Measure To Dampen Septic Inflammation Associated with COVID-19 Infection?
32582766 2020. Does Early Childhood Vaccination Protect Against COVID-19?
anybody remembers old lit on mcns: acacia akazien-extrakt nothing
Balneotherapy
32300868 ä. Balneotherapy and human immune function in the era of COVID-19
mycobacteria
32367857 2020. Safety of an immunomodulator Mycobacterium w in COVID-19
32493028 2020. Letter to the Editor: Repurposing of an Antisepsis Drug in COVID-19 Patients. PDF direct Mw ensues strong immune reaction and generates robust cytokines such as interleukin-2, interferon-γ, and T cell responses.
Helminthiosis
32358579 ä. Will helminth co-infection modulate COVID-19 severity in endemic regions?
immunomodulation immunotherapies
32380023 ä. Immunomodulation in COVID-19
32444269 ä. Immunotherapies for COVID-19: lessons learned from sepsis
32383371 2020. Perspectives of Immune Therapy in Coronavirus Disease 2019.
32499129 2020. Immunotherapies for COVID-19: Restoring the immunity could be the priority.
32452670 2020. Immunity-Boosting Spices and the Novel Coronavirus.
32468851 2020. Facing the SARS-CoV-2 outbreak in the immunotherapy era.
32534022 2020. COVID-19 and allergen immunotherapy: theoretical benefits invite to adjustments in practice recommendations.
C7190525 2020. Adjunct Immunotherapies for the Management of Severely Ill COVID-19 Patients
32404512 2020. Can Unconventional Immunomodulatory Agents Help Alleviate COVID-19 Symptoms and Severity?
32604407 2020. Immune modulation in COVID-19: Strategic considerations for personalized therapeutic intervention.
